Thursday, June 26
Session 1: 8:40 - 10:30 AM
Cardiogenic Shock is a continuum: learnings from the most recent studies
Moderators: Susanna Price (London, GBR), Phyllis Billia (Toronto, CAN), Stavros Drakos (Salt Lake City, USA)
Room : Auditorium
Continuum from Pre-shock to Shock – Erin Bohula (Boston, USA)
Serial Shock Assessment – Shashank Sinha (Falls Church, USA)
Biological Phenotypes are Key – Sabri Soussi (Toronto, CAN)
Devices Are Here to Stay – Pascal Le Prince (Paris, FRA) Universal Definition of CS: Are We Ready? – Alessandro Sionis (Barcelona, ESP) We Can Still Improve CS Trial Design – Antoine Kimmoun (Nancy, FRA) Industry perspective - Abiomed PMDA point of view
Panel discussion with all the above Additional panelist : Pietro Di Santo ( Ottawa, CAN), Rhonda Monroe (Charlotte, USA)
Fellows in charge of the scientific paper : Antoine Kimmoun (Nancy, FRA), Pablo Sanchez (San Francisco, USA)
Session 2 : 11:00 AM - 12:30 PM
Enriching the studied population to achieve “positive” RCTs
Moderators: David Baran (Fort Lauderdale, USA), Janine Pöss (Leipzig, DEU), Antoine Herpain (Brussels, BEL)
Invasive Hemodynamics remains key – Jan Belohlavek (Prague, CZE) Novel Biomarkers – Alexandre Mebazaa (Paris, FRA) Gender is key: learnings from ECLS-Shock – Uwe Zeymer (Ludwigshafen, DEU) Altshock2 – Guido Tavazzi (Pavia, ITA) Learnings from a large database – David Morrow (Boston, USA) New insights on Cardiogenic Shock Management in Japan - Naoki Sato (Tokyo, JAP)
Panel discussion with all the above Additional panelist : Pietro Di Santo ( Ottawa, CAN)
Session 3A : 1:30 - 2:30 PM
Ongoing trials in cardiogenic shock
Moderators: Hannah Schaubroeck (Brussels, BEL), Carlos Alviar (New York, USA)
Pre-recorded presentations: Procard 1B – Alexandre Mebazaa (Paris, FRA) INTeGRATE – Biykem Bozkurt (Houston, USA) DOREMI 2 – Rebecca Matthew (Ottawa, CAN) SEISMIC C – Matteo Pagnesi (Brescia, ITA) EmpaShock – Antoine Kimmoun (Nancy, FRA) Unload VA-ECMO + Impella – Dirk Westermann (Freiburg, DEU) LevoHeartShock – Bruno Levy (Nancy, FRA) CERAMICS – Mir Babar Basir (Detroit, USA) PACCS – Manreet Kanwar (Pittsburgh, USA) IV-cangrelor STEMI shock – Sarah Gorgis (Cleveland, USA) Dobermann - Sarah Holle (Copenhagen, DEN)
Panel discussion with all the above
Fellow in charge of the scientific paper : Florian Wenzl (Zürich, CHE), Sarah Holle (Copenhagen, DEN)
Session 4: 2:30 - 4:00 PM
Cardiogenic shock: joined efforts of regulators and trialists to achieve successful RCTs
Moderators: Mona Fiuzat (Arlington, USA), Uwe Zeymer (Ludwigshafen, DEU), Naoki Sato (Tokyo, JPN)
There is urgent need for successes in CS trials – Jacob Møller (Odense, DNK) In post-AMI patients – Holger Thiele (Leipzig, DEU) In post-advanced heart failure patients – Mandeep Mehra (Harvard, USA) We may match QOL and hard endpoints - Beth Davison (Momentum Research, USA) Mixed shock: ready for prime-time? – David Morrow (Boston, USA) Restoring safely systolic blood pressure is doable! – Jan Biegus (Wrocław, POL) Industry perspective - Steven Simonson (WindTree Tx, USA), Abiomed
Panel discussion with all the above
Session 5: 4:30 - 5:40 PM
AI will change the future of ICU
Moderators: Alexandre Mebazaa (Paris, FRA), Michelle Chew (Linköping, SWE)
Use of artificial intelligence in critical care: opportunities and obstacles – Michael R Pinsky (Pittsburgh, USA) Europe “INDICATE”s the ICU of the future – Christian Jung (Düsseldorf, DEU) ICU patients already benefit from AI – Gilles Clermont (Pittsburgh, USA) Regulators perspective - FDA, EMA, PMDA
Panel discussion with all the above
AI Innovation in ICU: 2025 Award for Startups : 5:40 - 7:30 PM
CONFERENCE DINNER : 7:30 - 9:30 PM
Friday, June 27
Session 6A: 8:30 - 10:00 AM
Acute heart failure: ready for personalized post-discharge
Moderators: Christopher O'Connor (Fairfax, USA), Ileana Piña (Philadelphia, USA)
Trial design to assess GDMT implementation – Harriette Van Spall (Hamilton, CAN) Devices and GDMT: the recipe for success – Biykem Bozkurt (Houston, USA) Modulating inflammation paths - Gad Cotter (Momentum Research, USA) MRA is reborn, what next? – Harriette Van Spall (Hamilton, CAN) Biomarkers to allow patients empowerment – Carolyn Rosner (Falls Church, USA) Improving QOL matters more than survival – Rhonda Monroe (Charlotte, USA) Industry Perspective - Léa Ricci (Roche), Katja Rohwedder (Bayer, USA), Medtronic
Panel discussion with all the above
Fellow in charge of the scientific paper : Jolie Bruno (Berne, SUI)
Session 7A: 10:30 AM - 12:00 PM
Life-threatening pulmonary hypertension: Hurray! there are successful trials
Moderators: Vallerie McLaughlin (Ann Arbor, USA), Arianna Colosio (Lancet Respiratory Medicine, GBR)
Novelties in PAH and right ventricular dysfunction – Anna Hemnes (Nashville, USA) Successes in life-threatening PAH: what secrets? – Marc Humbert (Paris, FRA) Endotyping PAH is the future – Laurent Savale (Paris, FRA) Ongoing trials in life-threatening PAH – Vallerie McLaughlin (Ann Arbor, USA) Novelties in acute pulmonary embolism – Riyaz Bashir (Philadelphia, USA) Industry Perspective, Patients Perspective, Regulators Perspective PMDA perspective on the novel therapies in PAH
Panel discussion with all the above
Fellows in charge of the scientific paper - Athenais Boucly (Paris, FRA), Deborah Gorth (Philadelphia, USA)
Session 8A: 1:00 - 3:00 PM
New directions in ARDS trials
Moderators: Arianna Colosio (Lancet Respiratory Medicine, GBR), Michael Matthay (San Francisco, USA), Gustavo Matute-Bello (NIH, USA)
Phase 3 trial assessing stem cell product MultiStem® - Eric Jenkins (Bellevue, USA) Real-time biomarker measures in ARDS is doable - Daniel Clark Files (Wake Forrest, USA) The PANTHER trial: First biomarker-guided trial in ARDS - Neil Aggarwal (Denver Colorado, USA) The DRIVE trial - Sarina Sahetya (Baltimore, USA) Biology studies in the Panther Trial – Narges Alipanah-Lechner (San Francisco, USA) Lung division support of ARDS, pneumonia & sepsis - Gustavo Matute-Bello (NIH, USA) Patient perspective - Eileen Rubin (Chicago, USA) Lessons from the ongoing ADCAP trial: enriching for more severe patients - Axel Vater (Aptarion Biotech, DEU) Industry Perspective - Negin Hajizadeh (Bayer, USA)
Panel discussion with all the above Additional panelist : Derek Russel (Birmingham, USA)
Fellows in charge of the scientific paper - Narges Alipanah-Lechner (San Francisco, USA), Charles de Roquetaillade (Paris, FRA)
Session 9A: 3:30 - 5:00 PM
Sepsis: ongoing trials testing new targets
Moderators: Wes Self (Nashville, USA), Michele Chew (Malmö, SWE), Claudia Dos Santos (Toronto, CAN)
Disseminated intravascular coagulation: pathophysiology - Jerrold Levy (Durham, USA) Disseminated intravascular coagulation: novel target – Nicole Juffermans (Amsterdam, NLD) Immunology – Benjamin Chousterman (Paris, FRA) Vasopressors – Ashish K. Khanna (Wake Forest, USA) Biomarker-guided therapy – Bruno François (Limoges, FRA) Pre-shock sepsis: phenotype matters – Nathan Shapiro (Groton, USA) Together we can dramatically improve the burden of sepsis - Jackie Duda (Frederick, USA) Industry perspective - Bayer PMDA Perspective on Sepsis and Septic Shock
Panel discussion with all the above Additional panelist : Nathan Nielsen
Fellows in charge of the scientific paper - Adrien Picod (Paris, FRA), Anaïs Caillard (Paris, FRA)
Click here to download the latest version of the scientific program :
For past editions’ scientific programs, click on the links below:
